A joint venture by Sony and Olympus, which makes medical equipment, will now proceed after the deal was delayed pending approval from China’s competition authority. The companies announced that they have now received all necessarily approval. Sony is investing $535 million into Olympus in efforts to increase its competitive stance within the medical equipment market. Olympus dominates about 70 percent of the sector, according to reports, despite being more well-known for its camera products. Additionally, while the two companies did not say which specific competition regulator was delaying the deal, sources confirmed to the media that it was China’s authority. The parties had originally planned to launch the venture on April 1.
Full Content: Google
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI